Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer

Bayer announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to the supplemental New Drug Application (sNDA) for regorafenib for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in the U.S.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news